Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xmt-1592
- Development stage
- Discontinued
- Lead developer
- Mersana Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
XMT-1592 is an investigational antibody-drug conjugate (ADC) developed using the Dolasynthen platform by Mersana Therapeutics. It targets sodium-dependent phosphate transport protein 2B (NaPi2b), which is highly expressed on certain tumor cells, including those in ovarian cancer and non-small cell lung cancer. The ADC consists of a proprietary NaPi2b-targeting antibody linked to an auristatin-based cytotoxic payload via the DolaLock mechanism, which allows for precise control of drug-to-antibody ratio and site-specific bioconjugation. Upon binding to NaPi2b-expressing tumor cells, XMT-1592 is internalized; the cytotoxic payload then inhibits tubulin polymerization, leading to mitotic arrest and apoptosis in targeted cancer cells. Preclinical studies demonstrated enhanced efficacy compared to earlier generation ADCs targeting the same antigen. Clinical development was discontinued during Phase 1 due to portfolio reprioritization.
- Other names
- anti-NaPi2b antibody-drug conjugate XMT-1592anti-NaPi-2b antibody-drug conjugate XMT-1592anti-NaPi 2b antibody-drug conjugate XMT-1592
02
Targets
SLC34A2 (Sodium-dependent phosphate transporter type IIb)
Beyond the preview
Go deeper on xmt-1592.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xmt-1592.